#### 16th July 2016 - Pune, India

"Update in management of Liver Diseases" was held at Pune, Maharashtra, India. The CME was organized by of Asian Society of Continuing Medical Education.

The sole objective of the CME was to update the Hepatologist and Consultant Physician about Alcoholic Liver diseases and Non Alcoholic Fatty Liver Disease with its complication and updates in management of liver diseases.

The session was open with an introductory session by Asian Society of Continuing Medical Education and followed by the scientific agenda.

**Date** <u>:</u> 16<sup>th</sup> July 2016.

**Venue** : Ambey Valley, Pune

Total Participants : 20

#### **TOPICS**

- 1. New Horizone In Hep C management
- 2. ALD with Ademethionine Treatment.
- 3. NASH with Ademethionine Treatment.

#### **FACULTIES**



- Dr Nitin Pai
- Dr Lalit Shimpi
- Dr Harshal Gadhikar
- Dr Udaysinh Patil

#### 1. Dr. Nitin Pai talked on New Horizone In Hep C management-

Summary of Dr. Nitin Pai talked –

Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors.

Course of oral direct-acting antiviral (DAA) treatment resulted in high virologic response rates post-treatment among Hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously.

### 2. Dr Lalit Shimpi talked on ALD With Ademethionine Treatment.

Summary of Dr. Lalit Shimpi talked –

S-adenosyl-l-methionine (SAMe; AdoMet) is an important, metabolically pleiotropic molecule that participates in multiple cellular reactions as the precursor for the synthesis of glutathione and principle methyl donor required for methylation of nucleic acids, phospholipids, histones, biogenic amines, and proteins. SAMe synthesis is depressed in chronic liver disease and so there has been considerable interest in the utility of SAMe to ameliorate disease severity.

Ademethionine belongs to a group of hepatoprotectors with antidepressive activity. Heptral exerts bile-expelling action, possesses detoxification, regeneration, anti oxidative, anti fibrosis and neuroprotective properties.

Ademetionine fills the deficiency of Ademetionine and stimulates its production in organism as well. Ademetionine takes part in



transmethylation reactions, increases the amount of glutamine in the liver, cysteine and turin in plasma. Ademiteonine also normalizes metabolic processes in the liver.

3. **Dr Harshal Gadhikar and Dr Udaysinh Patil** Talked on – NASH With Ademethionine Treatment.

Summary of Dr Harshal Gadhikar and Dr Udaysinh Patil talked –

Non-alcoholic steatohepatitis (NASH) is an self-regulating nosological entity, categorized by increased activity of liver enzymes in the blood and morphological changes in liver biopsy and similar changes as in alcoholic hepatitis – inflammation and fatty degeneration, not involving alcohol consumption by patients in quantities that cause liver damage. This disease has become the most common form among chronic liver diseases, reaching 60-95%.

Ademethionine is a pharmacological preparation with major constructive influence on the main pathogenic links of non-alcoholic steatohepatitis which justifies its use in this pathology. Additional inclusion of Ademethionine in the complex therapy of patients with NASH causes a more rapid elimination of the dyspeptic, pain and astheno-vegetative syndromes, improves lipid, carbohydrate and protein metabolisms, and eases liver detoxification function and improves the biochemical indices that characterize cytolytic and cholestatic syndromes. Heptral lacks adverse effects, which is important for its administration for both therapeutic and prophylactic purpose.

## **SNAPSHOTS**











## **SNAPSHOTS**









